newsfilter
← Latest News
Business Wire·

Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) today announced positive efficacy and safety data from the vibegron EMPOWUR long term extension study with patient data over a total exposure of 52 weeks. The data demonstrate that vibegron improved quality of life (QoL) and incontinence efficacy endpoints with good long term tolerability in adult patients with overactive bladder (OAB) and symptoms of urge urinary incontinence (UUI), urgency and urinary frequency.